<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DEXILANT - dexlansoprazole capsule, delayed release </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use DEXILANT safely and effectively. See full prescribing information for DEXILANT.<br> <br>DEXILANT (dexlansoprazole) delayed-release capsules, for oral use<br>Initial U.S. Approval: 1995 (lansoprazole)</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<a name="id_b2de0eed-ba27-42cc-b12c-3486419df588"></a><table>
<col align="left" width="75%">
<col align="right" width="25%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top">Indications and Usage</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><dl>
<dt> </dt>
<dd>Maintenance of Healed <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> (<a href="#i4i_section_ID_s1.2">1.2</a>)</dd>
</dl></td>
<td align="left" valign="top">06/2011</td>
</tr>
<tr>
<td align="left" valign="top">Warnings and Precautions</td>
<td align="left" valign="top"></td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"><dl>
<dt> </dt>
<dd>Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span> (<a href="#i4i_section_ID_s5.2">5.2</a>) </dd>
</dl></td>
<td align="left" valign="top">09/2010 <br>05/2011</td>
</tr>
</tbody>
</table>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">DEXILANT is a proton pump inhibitor (PPI) indicated for:  </p>
<ul>
<li>Healing of all grades of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> (EE). (<a href="#i4i_section_ID_s1.1">1.1</a>)</li>
<li>Maintaining healing of EE and relief of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>. (<a href="#i4i_section_ID_s1.2">1.2</a>)</li>
<li>Treating <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> associated with symptomatic non-erosive <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>). (<a href="#i4i_section_ID_s1.3">1.3</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>
<span class="Underline">Healing of EE:</span> 60 mg once daily for up to 8 weeks. (<a href="#i4i_section_ID_s2.1">2.1</a>)</li>
<li>
<span class="Underline">Maintenance of healed EE:</span> 30 mg once daily for up to 6 months. (<a href="#i4i_section_ID_s2.1">2.1</a>)</li>
<li>
<span class="Underline">Symptomatic non-erosive <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>:</span> 30 mg once daily for 4 weeks. (<a href="#i4i_section_ID_s2.1">2.1</a>)</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>:</span> Consider 30 mg maximum daily dose for patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class B). No studies were conducted in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class C). (<a href="#i4i_section_ID_s2.2">2.2</a>, <a href="#i4i_section_ID_s8.7">8.7</a>)</li>
<li>DEXILANT can be taken without regard to food. (<a href="#i4i_section_ID_s2.3">2.3</a>)</li>
<li>DEXILANT should be swallowed whole. Alternatively, capsules can be opened, sprinkled on one tablespoon of applesauce, and swallowed immediately. (<a href="#i4i_section_ID_s2.3">2.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Delayed-Release Capsules: 30 mg and 60 mg. (<a href="#i4i_dosage_form_strength_ID_s3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of the formulation. (<a href="#i4i_contraindications_ID_s4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">Gastric malignancy</span></span>: Symptomatic response with DEXILANT does not preclude the presence of <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">gastric malignancy</span>. (<a href="#i4i_section_ID_s5.1">5.1</a>)</li>
<li>
<span class="Underline">Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span>:</span> Long-term and multiple daily dose PPI therapy may be associated with an increased risk for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the hip, wrist or spine. (<a href="#i4i_section_ID_s5.2">5.2</a>)</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></span>: <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> has been reported rarely with prolonged treatment with PPIs. (<a href="#i4i_section_ID_s5.3">5.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most commonly reported adverse reactions (≥2%): <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>. (<a href="#i4i_section_ID_s6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals America, Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>
<span class="Underline">Atazanavir:</span> Do not co-administer with DEXILANT because atazanavir systemic concentrations may be substantially decreased. (<a href="#i4i_section_ID_s7.1">7.1</a>)</li>
<li>
<span class="Underline">Drugs with pH-dependent absorption (e.g., ampicillin esters, digoxin, iron salts, ketoconazole): </span>DEXILANT may interfere with absorption of drugs for which gastric pH is important for bioavailability. (<a href="#i4i_section_ID_s7.1">7.1</a>)</li>
<li>
<span class="Underline">Warfarin:</span> Patients taking concomitant warfarin may require monitoring for increases in international normalized ratio (INR) and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. (<a href="#i4i_section_ID_s7.2">7.2</a>)</li>
<li>
<span class="Underline">Tacrolimus:</span> Concomitant tacrolimus use may increase tacrolimus whole blood concentrations. (<a href="#i4i_section_ID_s7.3">7.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div><div><div></div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div><div></div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 2/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Maintenance of Healed <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Symptomatic Non-Erosive <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Important Administration Information</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">Gastric Malignancy</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Drugs with pH-Dependent Absorption Pharmacokinetics</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Warfarin</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Tacrolimus</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Clopidogrel</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Maintenance of Healed <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Symptomatic Non-Erosive <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_ID_s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></h2>
<p class="First">DEXILANT is indicated for healing of all grades of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> (EE) for up to 8 weeks. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Maintenance of Healed <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">DEXILANT is indicated to maintain healing of EE and relief of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> for up to 6 months.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Symptomatic Non-Erosive <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span></h2>
<p class="First">DEXILANT is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> associated with symptomatic non-erosive <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) for 4 weeks. </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dose</h2>
<p class="First">DEXILANT is available as capsules in 30 mg and 60 mg strengths for adult use. Directions for use in each indication are summarized in Table 1. </p>
<a name="table1"></a><table>
<caption><span>Table 1: DEXILANT Dosing Recommendations</span></caption>
<col align="center" width="33%">
<col align="center" width="34%">
<col align="center" width="33%">
<thead><tr class="Botrule First Last">
<td class="Rrule" align="left" valign="top">Indication</td>
<td class="Rrule" align="left" valign="top">Recommended Dose</td>
<td align="left" valign="top">Frequency</td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td class="Rrule" align="left" valign="top">Healing of EE</td>
<td class="Rrule" align="left" valign="top">60 mg</td>
<td align="left" valign="top">Once daily for up to 8 weeks</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Maintenance of Healed EE and relief of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span></td>
<td class="Rrule" align="left" valign="top">30 mg</td>
<td align="left" valign="top">Once daily
                                 </td>
</tr>
<tr class="Botrule Last">
<td class="Rrule" align="left" valign="top">Symptomatic Non-Erosive <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></td>
<td class="Rrule" align="left" valign="top">30 mg</td>
<td align="left" valign="top">Once daily for 4 weeks</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No adjustment for DEXILANT is necessary for patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class A). Consider a maximum daily dose of 30 mg for patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class B). No studies have been conducted in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class C) <span class="Italics">[see <a href="#i4i_section_ID_s8.7">Use in Specific Populations (8.7)</a> and <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Important Administration Information</h2>
<p class="First">DEXILANT can be taken without regard to food.</p>
<p>DEXILANT should be swallowed whole. </p>
<ul><li>Alternatively, DEXILANT capsules can be administered as follows:<ul>
<li>–Open capsule;</li>
<li>–Sprinkle intact granules on one tablespoon of applesauce;</li>
<li>– Swallow immediately. Granules should not be chewed. </li>
</ul>
</li></ul>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_ID_s3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul>
<li>30 mg delayed-release capsules are opaque, blue and gray with TAP and "30" imprinted on the capsule.</li>
<li>60 mg delayed-release capsules are opaque, blue with TAP and "60" imprinted on the capsule.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_ID_s4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">DEXILANT is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of the formulation <span class="Italics">[see <a href="#i4i_description_ID_s11">Description (11)</a>]</span>. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported with DEXILANT use <span class="Italics">[see <a href="#i4i_section_ID_s6.1">Adverse Reactions (6.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_ID_s5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">Gastric Malignancy</span></h2>
<p class="First">Symptomatic response with DEXILANT does not preclude the presence of <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">gastric malignancy</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Several published observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the hip, wrist or spine. The risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> should be managed according to established treatment guidelines <span class="Italics">[see <a href="#i4i_dosage_admin_ID_s2">Dosage and Administration (2)</a> and <a href="#i4i_adverse_effects_ID_s6">Adverse Reactions (6)</a>].</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span>, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy. Serious adverse events include <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. In most patients, treatment of <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> required magnesium replacement and discontinuation of the PPI. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically <span class="Italics">[see <a href="#i4i_section_ID_s6.2">Adverse Reactions (6.2)</a>].</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_ID_s6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The safety of DEXILANT was evaluated in 4548 patients in controlled and uncontrolled clinical studies, including 863 patients treated for at least 6 months and 203 patients treated for one year. Patients ranged in age from 18 to 90 years (median age 48 years), with 54% female, 85% Caucasian, 8% Black, 4% Asian, and 3% other races. Six randomized controlled clinical trials were conducted for the treatment of EE, maintenance of healed EE, and symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>, which included 896 patients on placebo, 455 patients on DEXILANT 30 mg, 2218 patients on DEXILANT 60 mg, and 1363 patients on lansoprazole 30 mg once daily. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8d2b213c-6d4f-4f49-a542-2453552005b5"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline">Most Commonly Reported Adverse Reactions</span></p>
<p>The most common adverse reactions (≥2%) that occurred at a higher incidence for DEXILANT than placebo in the controlled studies are presented in Table 2.</p>
<a name="table2"></a><table>
<caption><span>Table 2: Incidence of Adverse Reactions in Controlled Studies</span></caption>
<col align="left" width="33%">
<col align="center" width="13%">
<col align="center" width="13%">
<col align="center" width="13%">
<col align="center" width="13%">
<col align="center" width="15%">
<thead>
<tr class="First Toprule">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="left" valign="top">DEXILANT<br>30 mg</td>
<td class="Botrule Rrule" align="left" valign="top">DEXILANT<br>60 mg</td>
<td class="Botrule Rrule" align="left" valign="top">DEXILANT<br>Total</td>
<td class="Botrule Lrule" align="left" valign="top">Lansoprazole<br>30 mg</td>
</tr>
<tr class="Botrule Last">
<td class="Rrule" align="left" valign="top">Adverse Reaction</td>
<td class="Rrule" align="left" valign="top">(N=896)<br>%</td>
<td class="Rrule" align="left" valign="top">(N=455)<br>%</td>
<td class="Rrule" align="left" valign="top">(N=2218)<br>%</td>
<td class="Rrule" align="left" valign="top">(N=2621)<br>%</td>
<td align="left" valign="top">(N=1363)<br>%</td>
</tr>
</thead>
<tbody>
<tr class="First Toprule">
<td class="Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="left" valign="top">2.9</td>
<td class="Rrule" align="left" valign="top">5.1</td>
<td class="Rrule" align="left" valign="top">4.7</td>
<td class="Rrule" align="left" valign="top">4.8</td>
<td align="left" valign="top">3.2</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Rrule" align="left" valign="top">3.5</td>
<td class="Rrule" align="left" valign="top">3.5</td>
<td class="Rrule" align="left" valign="top">4.0</td>
<td class="Rrule" align="left" valign="top">4.0</td>
<td align="left" valign="top">2.6</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="left" valign="top">2.6</td>
<td class="Rrule" align="left" valign="top">3.3</td>
<td class="Rrule" align="left" valign="top">2.8</td>
<td class="Rrule" align="left" valign="top">2.9</td>
<td align="left" valign="top">1.8</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></td>
<td class="Rrule" align="left" valign="top">0.8</td>
<td class="Rrule" align="left" valign="top">2.9</td>
<td class="Rrule" align="left" valign="top">1.7</td>
<td class="Rrule" align="left" valign="top">1.9</td>
<td align="left" valign="top">0.8</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="left" valign="top">0.8</td>
<td class="Rrule" align="left" valign="top">2.2</td>
<td class="Rrule" align="left" valign="top">1.4</td>
<td class="Rrule" align="left" valign="top">1.6</td>
<td align="left" valign="top">1.1</td>
</tr>
<tr class="Botrule Last">
<td class="Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Rrule" align="left" valign="top">0.6</td>
<td class="Rrule" align="left" valign="top">2.6</td>
<td class="Rrule" align="left" valign="top">1.4</td>
<td class="Rrule" align="left" valign="top">1.6</td>
<td align="left" valign="top">1.2</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ba0b5b55-dce4-4b53-aafb-c0da79d16e35"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Underline">Adverse Reactions Resulting in Discontinuation</span></p>
<p>In controlled clinical studies, the most common adverse reaction leading to discontinuation from DEXILANT therapy was <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (0.7%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c204e6ff-7f59-43a1-9173-bec6e4fb9f68"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Underline">Other Adverse Reactions</span></p>
<p>Other adverse reactions that were reported in controlled studies at an incidence of less than 2% are listed below by body system:</p>
<p><span class="Italics">Blood and Lymphatic System Disorders:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>:</span> angina, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p>
<p><span class="Italics">Ear and Labyrinth Disorders: </span><span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="381299" conceptname="Swelling of structure of eye">eye swelling</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="197981" conceptname="Abdominal tenderness">abdominal tenderness</span>, <span class="product-label-link" type="condition" conceptid="437671" conceptname="Abnormal feces">abnormal feces</span>, anal <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, Barrett's esophagus, <span class="product-label-link" type="condition" conceptid="4198551" conceptname="Bezoar">bezoar</span>, <span class="product-label-link" type="condition" conceptid="197377" conceptname="Abnormal bowel sounds">bowel sounds abnormal</span>, <span class="product-label-link" type="condition" conceptid="4195873" conceptname="Breath smells unpleasant">breath odor</span>, <span class="product-label-link" type="condition" conceptid="4151446" conceptname="Lymphocytic-plasmacytic colitis">colitis microscopic</span>, <span class="product-label-link" type="condition" conceptid="4285898" conceptname="Polyp of colon">colonic polyp</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="433516" conceptname="Duodenitis">duodenitis</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, gastric <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyp</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span>, <span class="product-label-link" type="condition" conceptid="4010029" conceptname="Increased intestinal motility">gastrointestinal hypermotility</span> disorders, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>, GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and perforation, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span>, <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span>, <span class="product-label-link" type="condition" conceptid="4010028" conceptname="Impaired gastric emptying">impaired gastric emptying</span>, <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span>, <span class="product-label-link" type="condition" conceptid="4154941" conceptname="Mucus in stool">mucus stools</span>, oral mucosal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, <span class="product-label-link" type="condition" conceptid="4025947" conceptname="Pain associated with defecation">painful defecation</span>, <span class="product-label-link" type="condition" conceptid="4215578" conceptname="Proctitis">proctitis</span>, <span class="product-label-link" type="condition" conceptid="4015676" conceptname="Circumoral paresthesia">paresthesia oral</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4309379" conceptname="Retching">retching</span></p>
<p><span class="Italics">General Disorders and Administration Site Conditions:</span> adverse drug reaction, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">feeling abnormal</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucosal inflammation</span>, <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodule</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span></p>
<p><span class="Italics">Hepatobiliary Disorders:</span> <span class="product-label-link" type="condition" conceptid="4291807" conceptname="Biliary colic">biliary colic</span>, <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>: </span><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candida</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">oral herpes</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>, vulvo-<span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginal infection</span></p>
<p><span class="Italics">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span> and Procedural Complications:</span> <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>, <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, <span class="product-label-link" type="condition" conceptid="30234" conceptname="Neck sprain">joint sprains</span>, <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">procedural pain</span>, sunburn</p>
<p><span class="Italics">Laboratory Investigations:</span> ALP increased, ALT increased, AST increased, bilirubin decreased/increased, blood creatinine increased, blood gastrin increased, blood glucose increased, <span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">blood potassium</span> increased, <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">liver function test abnormal</span>, platelet count decreased, total protein increased, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increase</span></p>
<p><span class="Italics">Metabolism and Nutrition Disorders:</span> appetite changes, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span></p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> altered taste, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">psychomotor hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="379801" conceptname="Trigeminal neuralgia">trigeminal neuralgia</span></p>
<p><span class="Italics">Psychiatric Disorders: </span><span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, libido changes</p>
<p><span class="Italics">Renal and Urinary Disorders:</span> <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">micturition urgency</span></p>
<p><span class="Italics">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="439080" conceptname="Dyspareunia">dyspareunia</span>, <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>, <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorder</span></p>
<p><span class="Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnoea</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="4170108" conceptname="Respiratory tract congestion">respiratory tract congestion</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders: </span><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, pruritis, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesion</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span></p>
<p>Additional adverse reactions that were reported in a long-term uncontrolled study and were considered related to DEXILANT by the treating physician included: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, auditory <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, B-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span>, <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, <span class="product-label-link" type="condition" conceptid="194991" conceptname="Calculus of gallbladder with acute cholecystitis">cholecystitis acute</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, increased <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>, MCHC decrease, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4279274" conceptname="Rectal tenesmus">rectal tenesmus</span>, <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">restless legs syndrome</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span>.</p>
<p>Other adverse reactions not observed with DEXILANT, but occurring with the racemate lansoprazole can be found in the lansoprazole prescribing information, ADVERSE REACTIONS section.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval of DEXILANT. As these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics">Blood and Lymphatic System Disorders:</span> <span class="product-label-link" type="condition" conceptid="441269" conceptname="Autoimmune hemolytic anemia">autoimmune hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span></p>
<p><span class="Italics">Ear and Labyrinth Disorders:</span> <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span> oral <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span></p>
<p><span class="Italics">General Disorders and Administration Site Conditions:</span> facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></p>
<p><span class="Italics">Hepatobiliary Disorders:</span> drug-induced <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> (requiring emergency intervention), <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (some fatal)</p>
<p><span class="Italics">Metabolism and Nutrition Disorders:</span> <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span></p>
<p><span class="Italics">Musculoskeletal System Disorders:</span> bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, transient ischemic attack</p>
<p><span class="Italics">Renal and Urinary Disorders:</span> <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span></p>
<p><span class="Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4056883" conceptname="Edema of pharynx">pharyngeal edema</span>, <span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">throat tightness</span></p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders:</span> generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">leucocytoclastic vasculitis</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_ID_s7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Drugs with pH-Dependent Absorption Pharmacokinetics</h2>
<p class="First">DEXILANT causes inhibition of gastric acid secretion. DEXILANT is likely to substantially decrease the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance. Therefore, DEXILANT should not be co-administered with atazanavir. </p>
<p>DEXILANT may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Warfarin</h2>
<p class="First">Co-administration of DEXILANT 90 mg and warfarin 25 mg did not affect the pharmacokinetics of warfarin or INR <span class="Italics">[see <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>]</span>. However, there have been reports of increased INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients receiving PPIs and warfarin concomitantly. Increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time may lead to abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients treated with DEXILANT and warfarin concomitantly may need to be monitored for increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Tacrolimus</h2>
<p class="First">Concomitant administration of dexlansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Clopidogrel</h2>
<p class="First">Concomitant administration of dexlansoprazole and clopidogrel in healthy subjects had no clinically important effect on exposure to the active metabolite of clopidogrel or clopidogrel-induced platelet inhibition [<span class="Italics">see <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>].</span> No dose adjustment of clopidogrel is necessary when administered with an approved dose of DEXILANT.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_ID_s8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_ID_s8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_9426b5b8-6b3e-43b6-956d-eb7414a66476"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Underline"><span class="Bold">Teratogenic Effects</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0a01c416-aaf1-44ce-becb-1b5a956ca7c1"></a><a name="section-8.1.1.1"></a><p></p>
<p class="First">Pregnancy Category B. There are no adequate and well-controlled studies with dexlansoprazole in pregnant women. There were no adverse fetal effects in animal reproduction studies of dexlansoprazole in rabbits. Because animal reproduction studies are not always predictive of human response, DEXILANT should be used during pregnancy only if clearly needed.</p>
<p>A reproduction study conducted in rabbits at oral dexlansoprazole doses up to approximately 9 times the maximum recommended human dexlansoprazole dose (60 mg per day) revealed no evidence of impaired fertility or harm to the fetus due to dexlansoprazole. In addition, reproduction studies performed in pregnant rats with oral lansoprazole at doses up to 40 times the recommended human lansoprazole dose and in pregnant rabbits at oral lansoprazole doses up to 16 times the recommended human lansoprazole dose revealed no evidence of impaired fertility or harm to the fetus due to lansoprazole <span class="Italics">[see <a href="#i4i_animal_pharmacology_ID_s13.2">Nonclinical Toxicology (13.2)</a>]</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_ID_s8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether dexlansoprazole is excreted in human milk. However, lansoprazole and its metabolites are present in rat milk following the administration of lansoprazole. As many drugs are excreted in human milk, and because of the potential for tumorigenicity shown for lansoprazole in rat carcinogenicity studies <span class="Italics">[see <a href="#i4i_carcinogenesis_mutagenesis_fertility_ID_s13.1">Nonclinical Toxicology (13.1)</a>]</span>, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_ID_s8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of DEXILANT in pediatric patients (less than 18 years of age) have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_ID_s8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In clinical studies of DEXILANT, 11% of patients were aged 65 years and over. No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified significant differences in responses between geriatric and younger patients, but greater sensitivity of some older individuals cannot be ruled out <span class="Italics">[see <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dosage adjustment of DEXILANT is necessary in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The pharmacokinetics of dexlansoprazole in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> are not expected to be altered since dexlansoprazole is extensively metabolized in the liver to inactive metabolites, and no parent drug is recovered in the urine following an oral dose of dexlansoprazole <span class="Italics">[see <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No dosage adjustment for DEXILANT is necessary for patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class A). DEXILANT 30 mg should be considered for patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class B). No studies have been conducted in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class C) <span class="Italics">[see <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_ID_s10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There have been no reports of significant <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of DEXILANT. Multiple doses of DEXILANT 120 mg and a single dose of DEXILANT 300 mg did not result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or other severe adverse events. However, serious adverse events of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> have been reported in association with twice daily doses of DEXILANT 60 mg. Non-serious adverse reactions observed with twice daily doses of DEXILANT 60 mg include <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">contusion</span>, oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. Dexlansoprazole is not expected to be removed from the circulation by hemodialysis. If an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occurs, treatment should be symptomatic and supportive.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_ID_s11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">The active ingredient in DEXILANT (dexlansoprazole) delayed-release capsules, a proton pump inhibitor, is (+)-2-[(<span class="Italics">R</span>)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl] methyl} sulfinyl]-<span class="Italics">1H</span>-benzimidazole, a compound that inhibits gastric acid secretion. Dexlansoprazole is the <span class="Italics">R</span>-enantiomer of lansoprazole (a racemic mixture of the <span class="Italics">R</span>- and <span class="Italics">S</span>-enantiomers). Its empirical formula is: C<span class="Sub">16</span>H<span class="Sub">14</span>F<span class="Sub">3</span>N<span class="Sub">3</span>O<span class="Sub">2</span>S, with a molecular weight of 369.36. The structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d62d754e-2310-4912-b022-603ae925710d&amp;name=1dcfa9cd-b78d-496c-b61f-bbd6445ca0db-01.jpg"></div>
<p>Dexlansoprazole is a white to nearly white crystalline powder which melts with decomposition at 140°C. Dexlansoprazole is freely soluble in dimethylformamide, methanol, dichloromethane, ethanol, and ethyl acetate; and soluble in acetonitrile; slightly soluble in ether; and very slightly soluble in water; and practically insoluble in hexane.</p>
<p>Dexlansoprazole is stable when exposed to light. Dexlansoprazole is more stable in neutral and alkaline conditions than acidic conditions.</p>
<p>DEXILANT is supplied as a dual delayed-release formulation in capsules for oral administration. The capsules contain dexlansoprazole in a mixture of two types of enteric-coated granules with different pH-dependent dissolution profiles <span class="Italics">[see <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>DEXILANT is available in two dosage strengths: 30 mg and 60 mg, per capsule. Each capsule contains enteric-coated granules consisting of dexlansoprazole (active ingredient) and the following inactive ingredients: sugar spheres, magnesium carbonate, sucrose, low-substituted hydroxypropyl cellulose, titanium dioxide, hydroxypropyl cellulose, hypromellose 2910, talc, methacrylic acid copolymers, polyethylene glycol 8000, triethyl citrate, polysorbate 80, and colloidal silicon dioxide. The components of the capsule shell include the following inactive ingredients: hypromellose, carrageenan and potassium chloride. Based on the capsule shell color, blue contains FD&amp;C Blue No. 2 aluminum lake; gray contains black ferric oxide; and both contain titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_ID_s12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_ID_s12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Dexlansoprazole is a PPI that suppresses gastric acid secretion by specific inhibition of the (H<span class="Sup">+</span>,K<span class="Sup">+</span>)-ATPase in the gastric parietal cell. By acting specifically on the proton pump, dexlansoprazole blocks the final step of acid production.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_ID_s12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_412023e2-62cd-4b5c-a4a4-1689eba012f6"></a><a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Underline">Antisecretory Activity</span></p>
<p>The effects of DEXILANT 60 mg (n=20) or lansoprazole 30 mg (n=23) once daily for five days on 24-hour intragastric pH were assessed in healthy subjects in a multiple-dose crossover study. The results are summarized in Table 3.</p>
<a name="table3"></a><table>
<caption><span>Table 3: Effect on 24-hour Intragastric pH on Day 5 After Administration of DEXILANT or Lansoprazole</span></caption>
<col align="center" width="50%">
<col align="center" width="50%">
<thead><tr class="Botrule First Last">
<td class="Rrule" align="left" valign="top">DEXILANT 60 mg</td>
<td align="left" valign="top">Lansoprazole 30 mg</td>
</tr></thead>
<tbody>
<tr class="First Toprule"><td align="left" colspan="2" valign="top"><span class="Bold">Mean Intragastric pH</span></td></tr>
<tr>
<td class="Rrule" align="left" valign="top">4.55</td>
<td align="left" valign="top">4.13</td>
</tr>
<tr><td align="left" colspan="2" valign="top"><span class="Bold">% Time Intragastric pH &gt; 4<br>(hours)</span></td></tr>
<tr class="Botrule Last">
<td class="Rrule" align="left" valign="top">71<br>(17 hours)</td>
<td align="left" valign="top">60<br>(14 hours)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_78cd1c14-1eef-40fa-91bb-4e7b8a694294"></a><a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Underline">Serum Gastrin Effects</span></p>
<p>The effect of DEXILANT on serum gastrin concentrations was evaluated in approximately 3460 patients in clinical trials up to 8 weeks and in 1023 patients for up to 6 to 12 months. The mean fasting gastrin concentrations increased from baseline during treatment with DEXILANT 30 mg and 60 mg doses. In patients treated for more than 6 months, mean serum gastrin levels increased during approximately the first 3 months of treatment and were stable for the remainder of treatment. Mean serum gastrin levels returned to pre-treatment levels within one month of discontinuation of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fb38cc96-c2f0-49ae-b56f-259a14396911"></a><a name="section-11.2.3"></a><p></p>
<p class="First"><span class="Underline">Enterochromaffin-Like Cell (ECL) Effects</span></p>
<p>There were no reports of ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> in gastric biopsy specimens obtained from 653 patients treated with DEXILANT 30 mg, 60 mg or 90 mg for up to 12 months. </p>
<p>During lifetime exposure of rats dosed daily with up to 150 mg per kg per day of lansoprazole, marked <span class="product-label-link" type="condition" conceptid="4245637" conceptname="Hypergastrinemia">hypergastrinemia</span> was observed followed by ECL cell proliferation and formation of <span class="product-label-link" type="condition" conceptid="4304399" conceptname="Carcinoid tumor">carcinoid tumors</span>, especially in female rats <span class="Italics">[see <a href="#i4i_carcinogenesis_mutagenesis_fertility_ID_s13.1">Nonclinical Toxicology (13.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_66fd92ed-86b3-4823-84e1-f71bcf313970"></a><a name="section-11.2.4"></a><p></p>
<p class="First"><span class="Underline">Effect on Cardiac Repolarization</span></p>
<p>A study was conducted to assess the potential of DEXILANT to prolong the QT/QT<span class="Sub">c</span> interval in healthy adult subjects. DEXILANT doses of 90 mg or 300 mg did not delay cardiac repolarization compared to placebo. The positive control (moxifloxacin) produced statistically significantly greater mean maximum and time-averaged QT/QT<span class="Sub">c </span>intervals compared to placebo. </p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_ID_s12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The dual delayed release formulation of DEXILANT results in a dexlansoprazole plasma concentration-time profile with two distinct peaks; the first peak occurs 1 to 2 hours after administration, followed by a second peak within 4 to 5 hours (see <a href="#i4i__ID_fig1">Figure 1</a>). Dexlansoprazole is eliminated with a half-life of approximately 1 to 2 hours in healthy subjects and in patients with symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>. No accumulation of dexlansoprazole occurs after multiple, once daily doses of DEXILANT 30 mg or 60 mg, although mean AUC<span class="Sub">t</span> and C<span class="Sub">max</span> values of dexlansoprazole were slightly higher (less than 10%) on day 5 than on day 1.</p>
<div class="Warning">
<a name="id_706a9e46-7d43-4621-8698-191b4f3251ec"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold">Figure 1: Mean Plasma Dexlansoprazole Concentration – <br>Time Profile Following Oral Administration of 30 or 60 mg DEXILANT<br> Once Daily for 5 Days in Healthy Subjects</span></p>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d62d754e-2310-4912-b022-603ae925710d&amp;name=1dcfa9cd-b78d-496c-b61f-bbd6445ca0db-02.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="id_162c78e0-4f4a-47ff-bd61-cf213c23e9fe"></a><a name="section-11.3.1"></a><p></p>
<p class="First">The pharmacokinetics of dexlansoprazole are highly variable, with percent coefficient of variation (CV%) values for C<span class="Sub">max</span>, AUC, and CL/F of greater than 30% (see <a href="#table4">Table 4</a>).</p>
<a name="table4"></a><table>
<caption><span>Table 4: Mean (CV%) Pharmacokinetic Parameters for Subjects on Day 5 After Administration of DEXILANT</span></caption>
<col align="center" width="25%">
<col align="center" width="25%">
<col align="center" width="25%">
<col align="center" width="25%">
<thead><tr class="Botrule First Last">
<td class="Rrule" align="left" valign="top">Dose<br>(mg)</td>
<td class="Rrule" align="left" valign="top">C<span class="Sub">max</span><br>(ng/mL)</td>
<td class="Rrule" align="left" valign="top">AUC<span class="Sub">24</span><br>(ng∙h/mL)</td>
<td align="left" valign="top">CL/F<br>(L/h)</td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td class="Rrule" align="left" valign="top">30</td>
<td class="Rrule" align="left" valign="top">658 (40%)<br>(N=44)</td>
<td class="Rrule" align="left" valign="top">3275 (47%)<br>(N=43)</td>
<td align="left" valign="top">11.4 (48%)<br>(N=43)</td>
</tr>
<tr class="Botrule Last">
<td class="Rrule" align="left" valign="top">60</td>
<td class="Rrule" align="left" valign="top">1397 (51%)<br>(N=79)</td>
<td class="Rrule" align="left" valign="top">6529 (60%)<br>(N=73)</td>
<td align="left" valign="top">11.6 (46%)<br>(N=41)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7ef7d98e-6a04-4b38-90e2-80916fa54d75"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Absorption</span></p>
<p>After oral administration of DEXILANT 30 mg or 60 mg to healthy subjects and symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> patients, mean C<span class="Sub">max</span> and AUC values of dexlansoprazole increased approximately dose proportionally (see <a href="#i4i__ID_fig1">Figure 1</a>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a7bc7f91-3586-4e37-a6a2-ba2f7346883d"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Underline">Distribution</span></p>
<p>Plasma protein binding of dexlansoprazole ranged from 96.1% to 98.8% in healthy subjects and was independent of concentration from 0.01 to 20 mcg per mL. The apparent volume of distribution (V<span class="Sub">z</span>/F) after multiple doses in symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> patients was 40.3 L.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9eb4228b-6b7b-484c-a0ae-233ab8e23504"></a><a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Underline">Metabolism</span></p>
<p>Dexlansoprazole is extensively metabolized in the liver by oxidation, reduction, and subsequent formation of sulfate, glucuronide and glutathione conjugates to inactive metabolites. Oxidative metabolites are formed by the cytochrome P450 (CYP) enzyme system including hydroxylation mainly by CYP2C19, and oxidation to the sulfone by CYP3A4. </p>
<p>CYP2C19 is a polymorphic liver enzyme which exhibits three phenotypes in the metabolism of CYP2C19 substrates; extensive metabolizers (*1/*1), intermediate metabolizers (*1/mutant) and poor metabolizers (mutant/mutant). Dexlansoprazole is the major circulating component in plasma regardless of CYP2C19 metabolizer status. In CYP2C19 intermediate and extensive metabolizers, the major plasma metabolites are 5-hydroxy dexlansoprazole and its glucuronide conjugate, while in CYP2C19 poor metabolizers dexlansoprazole sulfone is the major plasma metabolite.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7f5b8fd4-91c7-4b96-ba22-490d42559a93"></a><a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Underline">Elimination</span></p>
<p>Following the administration of DEXILANT, no unchanged dexlansoprazole is excreted in urine. Following the administration of [<span class="Sup">14</span>C]dexlansoprazole to 6 healthy male subjects, approximately 50.7% (standard deviation (SD): 9.0%) of the administered radioactivity was excreted in urine and 47.6% (SD: 7.3%) in the feces. Apparent clearance (CL/F) in healthy subjects was 11.4 to 11.6 L/h, respectively, after 5-days of 30 or 60 mg once daily administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_85371f03-7e7e-4569-92b7-68292d934cda"></a><a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Underline">Effect of CYP2C19 Polymorphism on Systemic Exposure of Dexlansoprazole</span></p>
<p>Systemic exposure of dexlansoprazole is generally higher in intermediate and poor metabolizers. In male Japanese subjects who received a single dose of DEXILANT 30 mg or 60 mg (N=2 to 6 subjects/group), mean dexlansoprazole C<span class="Sub">max</span> and AUC values were up to 2 times higher in intermediate compared to extensive metabolizers; in poor metabolizers, mean C<span class="Sub">max</span> was up to 4 times higher and mean AUC was up to 12 times higher compared to extensive metabolizers. Though such study was not conducted in Caucasians and African Americans, it is expected dexlansoprazole exposure in these races will be affected by CYP2C19 phenotypes as well.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s12.4"></a><a name="section-11.4"></a><p></p>
<p class="First"><span class="Underline">Effect of Food on Pharmacokinetics and Pharmacodynamics</span></p>
<p>In food-effect studies in healthy subjects receiving DEXILANT under various fed conditions compared to fasting, increases in C<span class="Sub">max</span> ranged from 12% to 55%, increases in AUC ranged from 9% to 37%, and t<span class="Sub">max</span> varied (ranging from a decrease of 0.7 hours to an increase of 3 hours). No significant differences in mean intragastric pH were observed between fasted and various fed conditions. However, the percentage of time intragastric pH exceeded 4 over the 24-hour dosing interval decreased slightly when DEXILANT was administered after a meal (57%) relative to fasting (64%), primarily due to a decreased response in intragastric pH during the first 4 hours after dosing. Because of this, while DEXILANT can be taken without regard to food, some patients may benefit from administering the dose prior to a meal if post-meal symptoms do not resolve under post-fed conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s12.5"></a><a name="section-11.5"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Special Populations</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3c40a046-1eaf-4fa8-8be4-109b7265d259"></a><a name="section-11.5.1"></a><p></p>
<p class="First"><span class="Underline">Pediatric Use</span></p>
<p>The pharmacokinetics of dexlansoprazole in patients under the age of 18 years have not been studied. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0a793a1b-881c-4129-b690-a8be3a9cf202"></a><a name="section-11.5.2"></a><p></p>
<p class="First"><span class="Underline">Geriatric Use</span></p>
<p>The terminal elimination half-life of dexlansoprazole is significantly increased in geriatric subjects compared to younger subjects (2.23 and 1.5 hours, respectively); this difference is not clinically relevant. Dexlansoprazole exhibited higher systemic exposure (AUC) in geriatric subjects (34.5% higher) than younger subjects. No dosage adjustment is needed in geriatric patients <span class="Italics">[see <a href="#i4i_geriatric_use_ID_s8.5">Use in Specific Populations (8.5)</a>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8aa0ff54-010c-47b9-b261-4a61f73b98f4"></a><a name="section-11.5.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>Dexlansoprazole is extensively metabolized in the liver to inactive metabolites, and no parent drug is recovered in the urine following an oral dose of dexlansoprazole. Therefore, the pharmacokinetics of dexlansoprazole are not expected to be altered in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and no studies were conducted in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#i4i_section_ID_s8.6">Use in Specific Populations (8.6)</a>]</span>. In addition, the pharmacokinetics of lansoprazole were studied in patients with mild, moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>; results demonstrated no need for a dose adjustment for this patient population<span class="Bold">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_776ddd52-0ee4-4c3d-8fc5-e6fd8fa718e0"></a><a name="section-11.5.4"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>In a study of 12 patients with moderately impaired hepatic function who received a single oral dose of DEXILANT 60 mg, plasma exposure (AUC) of bound and unbound dexlansoprazole in the <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> group was approximately 2 times greater compared to subjects with normal hepatic function. This difference in exposure was not due to a difference in protein binding between the two liver function groups. No adjustment for DEXILANT is necessary for patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class A). DEXILANT 30 mg should be considered for patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class B). No studies have been conducted in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class C) <span class="Italics">[see <a href="#i4i_section_ID_s8.7">Use in Specific Populations (8.7)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cb84004d-3dc2-4bd3-b161-0681f563bdbb"></a><a name="section-11.5.5"></a><p></p>
<p class="First"><span class="Underline">Gender</span></p>
<p>In a study of 12 male and 12 female healthy subjects who received a single oral dose of DEXILANT 60 mg, females had higher systemic exposure (AUC) (42.8% higher) than males. No dosage adjustment is necessary in patients based on gender.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s12.6"></a><a name="section-11.6"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Drug-Drug Interactions</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a89d7ae8-9fc8-4109-aa72-a6f522312d12"></a><a name="section-11.6.1"></a><p></p>
<p class="First"><span class="Underline">Warfarin </span></p>
<p>In a study of 20 healthy subjects, co-administration of DEXILANT 90 mg once daily for 11 days with a single 25 mg oral dose of warfarin on day 6 did not result in any significant differences in the pharmacokinetics of warfarin or INR compared to administration of warfarin with placebo. However, there have been reports of increased INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients receiving PPIs and warfarin concomitantly <span class="Italics">[see <a href="#i4i_section_ID_s7.2">Drug Interactions (7.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5d6dc6c7-d6dc-4376-aa93-a9702fa82cde"></a><a name="section-11.6.2"></a><p></p>
<p class="First"><span class="Underline">Cytochrome P 450 Interactions </span></p>
<p>Dexlansoprazole is metabolized, in part, by CYP2C19 and CYP3A4 <span class="Italics">[see <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>]</span>. </p>
<p>In vitro studies have shown that dexlansoprazole is not likely to inhibit CYP isoforms 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 2E1 or 3A4. As such, no clinically relevant interactions with drugs metabolized by these CYP enzymes would be expected. Furthermore, in vivo studies showed that DEXILANT did not have an impact on the pharmacokinetics of coadministered phenytoin (CYP2C9 substrate) or theophylline (CYP1A2 substrate). The subjects' CYP1A2 genotypes in the drug-drug interaction study with theophylline were not determined. Although in vitro studies indicated that DEXILANT has the potential to inhibit CYP2C19 in vivo, an in vivo drug-drug interaction study in mainly CYP2C19 extensive and intermediate metabolizers has shown that DEXILANT does not affect the pharmacokinetics of diazepam (CYP2C19 substrate). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_13a19847-f403-4885-8b32-97c9e1792192"></a><a name="section-11.6.3"></a><p></p>
<p class="First"><span class="Underline">Clopidogrel</span></p>
<p>Clopidogrel is metabolized to its active metabolite in part by CYP2C19. A study of healthy subjects who were CYP2C19 extensive metabolizers, receiving once daily administration of clopidogrel 75 mg alone or concomitantly with DEXILANT 60 mg (n=40), for 9 days was conducted. The mean AUC of the active metabolite of clopidogrel was reduced by approximately 9% (mean AUC ratio was 91%, with 90% CI of 86-97%) when DEXILANT was coadministered compared to administration of clopidogrel alone. Pharmacodynamic parameters were also measured and demonstrated that the change in inhibition of platelet aggregation (induced by 5 mcM ADP) was related to the change in the exposure to clopidogrel active metabolite. The clinical significance of this finding is not clear.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_ID_s13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_ID_s13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">The carcinogenic potential of dexlansoprazole was assessed using lansoprazole studies. In two 24-month carcinogenicity studies, Sprague-Dawley rats were treated orally with lansoprazole at doses of 5 to 150 mg per kg per day, about 1 to 40 times the exposure on a body surface (mg/m<span class="Sup">2</span>) basis of a 50 kg person of average height [1.46 m<span class="Sup">2 </span> body surface area (BSA)] given the recommended human dose of lansoprazole 30 mg per day. </p>
<p>Lansoprazole produced dose-related gastric ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and ECL cell carcinoids in both male and female rats <span class="Italics">[see <a href="#i4i_pharmacodynamics_ID_s12.2">Clinical Pharmacology (12.2)</a>].</span></p>
<p>In rats, lansoprazole also increased the incidence of intestinal <span class="product-label-link" type="condition" conceptid="4070551" conceptname="Metaplasia">metaplasia</span> of the gastric epithelium in both sexes. In male rats, lansoprazole produced a dose-related increase of testicular interstitial cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span>. The incidence of these <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in rats receiving doses of 15 to 150 mg per kg per day (4 to 40 times the recommended human lansoprazole dose based on BSA) exceeded the low background incidence (range = 1.4 to 10%) for this <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of rat. </p>
<p>In a 24-month carcinogenicity study, CD-1 mice were treated orally with lansoprazole doses of 15 to 600 mg per kg per day, 2 to 80 times the recommended human lansoprazole dose based on BSA. Lansoprazole produced a dose-related increased incidence of gastric ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>. It also produced an increased incidence of <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span> (<span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenoma</span> plus carcinoma). The tumor incidences in male mice treated with 300 and 600 mg lansoprazole per kg per day (40 to 80 times the recommended human lansoprazole dose based on BSA) and female mice treated with 150 to 600 mg lansoprazole per kg per day (20 to 80 times the recommended human lansoprazole dose based on BSA) exceeded the ranges of background incidences in historical controls for this <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of mice. Lansoprazole treatment produced <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span> of rete testis in male mice receiving 75 to 600 mg per kg per day (10 to 80 times the recommended human lansoprazole dose based on BSA).</p>
<p>A 26-week p53 (+/-) transgenic mouse carcinogenicity study of lansoprazole was not positive.</p>
<p>Lansoprazole was positive in the Ames test and the <span class="Italics">in vitro</span> human lymphocyte chromosomal aberration assay. Lansoprazole was not genotoxic in the <span class="Italics">ex vivo</span> rat hepatocyte unscheduled DNA synthesis (UDS) test, the <span class="Italics">in vivo</span> mouse micronucleus test or the rat bone marrow cell chromosomal aberration test.</p>
<p>Dexlansoprazole was positive in the Ames test and in the <span class="Italics">in vitro </span>chromosome aberration test using Chinese hamster lung cells. Dexlansoprazole was negative in the <span class="Italics">in vivo</span> mouse micronucleus test. </p>
<p>The potential effects of dexlansoprazole on fertility and reproductive performance were assessed using lansoprazole studies. Lansoprazole at oral doses up to 150 mg per kg per day (40 times the recommended human lansoprazole dose based on BSA) was found to have no effect on fertility and reproductive performance of male and female rats.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_ID_s13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_661bfc18-1378-4045-b581-fdb49861284b"></a><a name="section-12.2.1"></a><p></p>
<p class="First">Reproductive Toxicology Studies</p>
<p>A reproduction study conducted in rabbits at oral dexlansoprazole doses up to 30 mg per kg per day (approximately 9 times the maximum recommended human dexlansoprazole dose [60 mg per day] based on BSA) revealed no evidence of impaired fertility or harm to the fetus due to dexlansoprazole. In addition, reproduction studies performed in pregnant rats with oral lansoprazole at doses up to 150 mg per kg per day (40 times the recommended human lansoprazole dose based on BSA) and in pregnant rabbits at oral lansoprazole doses up to 30 mg per kg per day (16 times the recommended human lansoprazole dose based on BSA) revealed no evidence of impaired fertility or harm to the fetus due to lansoprazole.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_ID_s14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></h2>
<p class="First">Two multi-center, double-blind, active-controlled, randomized, 8-week studies were conducted in patients with endoscopically confirmed EE. Severity of the disease was classified based on the Los Angeles Classification Grading System (Grades A-D). Patients were randomized to one of the following three treatment groups: DEXILANT 60 mg daily, DEXILANT 90 mg daily or lansoprazole 30 mg daily. Patients who were <span class="Italics">H. pylori </span>positive or who had Barrett's Esophagus and/or definite dysplastic changes at baseline were excluded from these studies. A total of 4092 patients were enrolled and ranged in age from 18 to 90 years (median age 48 years) with 54% male. Race was distributed as follows: 87% Caucasian, 5% Black and 8% other. Based on the Los Angeles Classification, 71% of patients had mild EE (Grades A and B) and 29% of patients had moderate to severe EE (Grades C and D) before treatment.</p>
<p>The studies were designed to test non-inferiority. If non-inferiority was demonstrated then superiority would be tested. Although non-inferiority was demonstrated in both studies, the finding of superiority in one study was not replicated in the other.</p>
<p>The proportion of patients with healed EE at week 4 or 8 is presented below in Table 5. </p>
<a name="table5"></a><table>
<caption><span>Table 5: EE Healing Rates: All Grades</span></caption>
<col align="center" width="8%">
<col align="center" width="15%">
<col align="center" width="25%">
<col align="center" width="15%">
<col align="center" width="15%">
<col align="center" width="22%">
<thead><tr class="Botrule First Last">
<td class="Lrule Rrule" align="left" valign="bottom">Study</td>
<td class="Rrule" align="left" valign="bottom">Number of Patients<br>(N)
                                 </td>
<td class="Rrule" align="left" valign="bottom">Treatment Group<br>(daily)</td>
<td class="Rrule" align="left" valign="bottom">Week 4<br>% Healed</td>
<td class="Rrule" align="left" valign="bottom">Week 8
                                    <br>% Healed</td>
<td class="Rrule" align="left" valign="top">(95% CI) for the Treatment Difference (DEXILANT– Lansoprazole) by Week 8 </td>
</tr></thead>
<tfoot>
<tr class="Last"><td class="Lrule Rrule" align="left" colspan="6" valign="top">CI = Confidence interval</td></tr>
<tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Demonstrated non-inferiority to lansoprazole</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" rowspan="2" valign="top"><span class="Bold">1</span></td>
<td class="Rrule" align="left" valign="top">657</td>
<td class="Rrule" align="left" valign="top">DEXILANT 60 mg</td>
<td class="Rrule" align="left" valign="top">70</td>
<td class="Rrule" align="left" valign="top">87</td>
<td class="Rrule" align="left" rowspan="2" valign="top">(-1.5, 6.1)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">648</td>
<td class="Rrule" align="left" valign="top">Lansoprazole 30 mg</td>
<td class="Rrule" align="left" valign="top">65</td>
<td class="Rrule" align="left" valign="top">85</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" rowspan="2" valign="top"><span class="Bold">2</span></td>
<td class="Rrule" align="left" valign="top">639</td>
<td class="Rrule" align="left" valign="top">DEXILANT 60 mg</td>
<td class="Rrule" align="left" valign="top">66</td>
<td class="Rrule" align="left" valign="top">85</td>
<td class="Rrule" align="left" rowspan="2" valign="top">(2.2, 10.5)<a href="#footnote-1" class="Sup">*</a>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="top">656</td>
<td class="Rrule" align="left" valign="top">Lansoprazole 30 mg</td>
<td class="Rrule" align="left" valign="top">65</td>
<td class="Rrule" align="left" valign="top">79</td>
</tr>
</tbody>
</table>
<p>DEXILANT 90 mg was studied and did not provide additional clinical benefit over DEXILANT 60 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Maintenance of Healed <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></h2>
<p class="First">A multi-center, double-blind, placebo-controlled, randomized study was conducted in patients who successfully completed an EE study and showed endoscopically confirmed healed EE. Maintenance of healing and symptom resolution over a six-month period were evaluated with DEXILANT 30 mg or 60 mg once daily compared to placebo. A total of 445 patients were enrolled and ranged in age from 18 to 85 years (median age 49 years), with 52% female. Race was distributed as follows: 90% Caucasian, 5% Black and 5% other.</p>
<p> Sixty-six percent of patients treated with 30 mg of DEXILANT remained healed over the six-month time period as confirmed by endoscopy (see <a href="#table6">Table 6</a>). </p>
<a name="table6"></a><table>
<caption><span>Table 6: Maintenance Rates of Healed EE at Month 6</span></caption>
<col align="center" width="34%">
<col align="center" width="33%">
<col align="center" width="33%">
<thead><tr class="Botrule First Last">
<td class="Rrule" align="left" valign="top">Number of Patients <br> (N)
                                 </td>
<td class="Rrule" align="left" valign="top">Treatment Group <br> (daily) </td>
<td align="left" valign="top"> Maintenance Rate <br> (%) </td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td class="Rrule" align="left" valign="top">125</td>
<td class="Rrule" align="left" valign="top">DEXILANT 30 mg</td>
<td align="left" valign="top">66.4
                                 </td>
</tr>
<tr class="Botrule Last">
<td class="Rrule" align="left" valign="top">119</td>
<td class="Rrule" align="left" valign="top">Placebo</td>
<td align="left" valign="top">14.3</td>
</tr>
</tbody>
</table>
<p>DEXILANT 60 mg was studied and did not provide additional clinical benefit over DEXILANT 30 mg. </p>
<p>The effect of DEXILANT 30 mg on maintenance of relief of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> was also evaluated. Upon entry into the maintenance study, a majority of patients' baseline <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> severity was rated as none. DEXILANT 30 mg demonstrated a statistically significantly higher percent of 24-hour <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>-free periods compared to placebo over the 6-month treatment period (see <a href="#tbl7">Table 7</a>). The majority of patients treated with placebo discontinued due to relapse of EE between month two and month six.</p>
<a name="tbl7"></a><table>
<caption><span>Table 7: Median Percentage of 24-Hour <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span>-Free Periods of the Maintenance of Healed EE Study</span></caption>
<col align="center" width="15%">
<col align="center" width="14%">
<col align="center" width="14%">
<col align="center" width="14%">
<col align="center" width="14%">
<col align="center" width="14%">
<col align="center" width="15%">
<thead>
<tr class="First Toprule">
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Overall Treatment
                                 </td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Month 1</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top">Month 6</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top">Treatment Group <br>(daily)</td>
<td class="Rrule" align="left" valign="top">N</td>
<td class="Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span>-Free 24-hour Periods <br>(%)</td>
<td class="Rrule" align="left" valign="top">N</td>
<td class="Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span>-Free 24-hour Periods <br>(%)</td>
<td class="Rrule" align="left" valign="top">N</td>
<td class="Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span>-Free 24-hour Periods <br> (%)</td>
</tr>
</thead>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" valign="top">DEXILANT 30 mg</td>
<td class="Rrule" align="left" valign="top">132</td>
<td class="Rrule" align="left" valign="top">96.1 
                                 </td>
<td class="Rrule" align="left" valign="top">126</td>
<td class="Rrule" align="left" valign="top">96.7</td>
<td class="Rrule" align="left" valign="top">80</td>
<td class="Rrule" align="left" valign="top">98.3</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Rrule" align="left" valign="top">141</td>
<td class="Rrule" align="left" valign="top">28.6</td>
<td class="Rrule" align="left" valign="top">117</td>
<td class="Rrule" align="left" valign="top">28.6</td>
<td class="Rrule" align="left" valign="top">23</td>
<td class="Rrule" align="left" valign="top">73.3</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Symptomatic Non-Erosive <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></h2>
<p class="First">A multi-center, double-blind, placebo-controlled, randomized, 4-week study was conducted in patients with a diagnosis of symptomatic non-erosive <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> made primarily by presentation of symptoms. These patients who identified <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> as their primary symptom, had a history of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> for 6 months or longer, had <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> on at least 4 of 7 days immediately prior to randomization and had no <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">esophageal erosions</span> as confirmed by endoscopy. However, patients with symptoms which were not acid-related may not have been excluded using these inclusion criteria. Patients were randomized to one of the following treatment groups: DEXILANT 30 mg daily, 60 mg daily, or placebo. A total of 947 patients were enrolled and ranged in age from 18 to 86 years (median age 48 years) with 71% female. Race was distributed as follows: 82% Caucasian, 14% Black and 4% other.</p>
<p>DEXILANT 30 mg provided statistically significantly greater percent of days with <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>-free 24-hour periods over placebo as assessed by daily diary over 4 weeks (see <a href="#tble8">Table 8</a>). DEXILANT 60 mg was studied and provided no additional clinical benefit over DEXILANT 30 mg.</p>
<a name="tble8"></a><table>
<caption><span>Table 8: Median Percentages of 24-Hour <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span>-Free Periods During the 4 Week Treatment Period of the Symptomatic Non-Erosive <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> Study</span></caption>
<col align="center" width="34%">
<col align="center" width="33%">
<col align="center" width="33%">
<thead><tr class="Botrule First Last">
<td class="Rrule" align="left" valign="top"> N </td>
<td class="Rrule" align="left" valign="top"> Treatment Group <br> (daily) </td>
<td align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span>-Free <br> 24-hour Periods <br> (%) </td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td class="Rrule" align="left" valign="top">312</td>
<td class="Rrule" align="left" valign="top">DEXILANT 30 mg</td>
<td align="left" valign="top">54.9
                                 </td>
</tr>
<tr class="Botrule Last">
<td class="Rrule" align="left" valign="top">310</td>
<td class="Rrule" align="left" valign="top">Placebo</td>
<td align="left" valign="top">18.5</td>
</tr>
</tbody>
</table>
<p>A higher percentage of patients on DEXILANT 30 mg had <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>-free 24-hour periods compared to placebo as early as the first three days of treatment and this was sustained throughout the treatment period (percentage of patients on Day 3: DEXILANT 38% versus placebo 15%; on Day 28: DEXILANT 63% versus placebo 40%).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_ID_s16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">DEXILANT delayed-release capsules, 60 mg, are opaque, blue with TAP and "60" imprinted on the capsule and supplied as:</p>
<a name="id_a1af640b-3fd3-4d6a-b243-23b11cc4b08f"></a><table>
<col align="left" width="30%">
<col align="left" width="70%">
<thead><tr class="First Last">
<td align="left"><span class="Underline"><span class="Bold">NDC Number</span></span></td>
<td align="left"><span class="Underline"><span class="Bold">Size</span></span></td>
</tr></thead>
<tbody><tr class="First Last">
<td align="left">54868-6152-0</td>
<td align="left">Bottle of 30</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_61441145-225f-4c57-84a3-499468ddb79f"></a><a name="section-14.1"></a><p></p>
<p class="First">Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_ID_s17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">"See <a href="#i4i_patient_package_insert_ID_patient_labeling">FDA-Approved Patient Labeling</a> (Patient Information)"</p>
<p>To ensure the safe and effective use of DEXILANT, this information and instructions provided in the FDA-approved Patient Information Leaflet should be discussed with the patient. </p>
<p>Inform the patient to watch for signs of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> as these could be serious and may require that DEXILANT be discontinued.</p>
<p>Advise the patient to immediately report and seek care for any cardiovascular or neurological symptoms including <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span> as these may be signs of <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> <span class="Italics">[see <a href="#i4i_section_ID_s5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
<p>Advise the patient to tell their health care provider if they take atazanavir, tacrolimus, warfarin and drugs that are affected by gastric pH changes <span class="Italics">[see <a href="#i4i_interactions_ID_s7">Drug Interactions (7)</a>]</span></p>
<p>Advise the patient to follow the dosing instructions in the Patient Information Leaflet and inform the patient that:</p>
<ul>
<li>DEXILANT is available as a delayed-release capsule.</li>
<li>DEXILANT may be taken without regard to food.</li>
<li>DEXILANT should be swallowed whole.</li>
<li>Alternatively, DEXILANT capsules can be administered as follows: <ul>
<li>–Open capsule;</li>
<li>–Sprinkle intact granules on one tablespoon of applesauce;</li>
<li>–Swallow immediately. Granules should not be chewed.</li>
<li>–Do not store for later use.</li>
</ul>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_ID_patient_labeling"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">FDA-Approved Patient Labeling</span></p>
<p><span class="Bold">Patient Information</span></p>
<p><span class="Bold">DEXILANT (decks-ĭ-launt)<br>(dexlansoprazole)<br>delayed-release capsules</span></p>
<p>Read the Patient Information that comes with DEXILANT before you start taking it and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.</p>
<p><span class="Bold">What is DEXILANT?</span></p>
<p>DEXILANT is a prescription medicine called a proton pump inhibitor (PPI). DEXILANT reduces the amount of acid in your stomach.</p>
<p>DEXILANT is used in adults:</p>
<ul>
<li>for up to 8 weeks to heal acid-related damage to the lining of the esophagus (called <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> or EE).</li>
<li>for up to 6 months to continue healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> and relief of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>.</li>
<li>for 4 weeks to treat <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> related to <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>).</li>
</ul>
<p><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> happens when acid from your stomach enters the tube (esophagus) that connects your mouth to your stomach. This may cause a burning feeling in your chest or throat, sour taste or burping.</p>
<p>In some cases, acid can damage the lining of your esophagus. This damage is called <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> or EE.</p>
<p>DEXILANT may help your acid-related symptoms, but you could still have serious stomach problems. Talk with your doctor.</p>
<p>It is not known if DEXILANT is safe and effective in children under 18 years of age.</p>
<p><span class="Bold">Who should not take DEXILANT?</span></p>
<p>Do not take DEXILANT if you are allergic to DEXILANT or any of its ingredients. See the end of this leaflet for a complete list of ingredients in DEXILANT. </p>
<p><span class="Bold">What should I tell my doctor before taking DEXILANT?</span></p>
<p><span class="Bold">Before you take DEXILANT, tell your doctor if you:</span></p>
<ul>
<li>have been told that you have low magnesium levels in your blood</li>
<li>have liver problems</li>
<li>have any other medical conditions</li>
<li>are pregnant or plan to become pregnant. It is not known if DEXILANT will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant.</li>
<li>are breast-feeding or planning to breast-feed. You and your doctor should decide if you will take DEXILANT or breast-feed. You should not do both without first talking with your doctor.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take</span>, including prescription and non-prescription medicines, vitamins, and herbal supplements. DEXILANT may affect how other medicines work, and other medicines may affect how DEXILANT works. Especially tell your doctor if you take:</p>
<ul>
<li>ampicillin sodium (Unasyn) or ampicillin trihydrate (Principen)</li>
<li>atazanavir (Reyataz)</li>
<li>digoxin (Lanoxin)</li>
<li>a product that contains iron</li>
<li>ketoconazole (Nizoral)</li>
<li>warfarin (Coumadin, Jantoven)</li>
<li>tacrolimus (Prograf)</li>
</ul>
<p>Ask your doctor or pharmacist if you are not sure if your medicine is listed above.</p>
<p><span class="Bold">How should I take DEXILANT?</span></p>
<ul>
<li>Take DEXILANT exactly as prescribed by your doctor.</li>
<li>Do not change your dose or stop taking DEXILANT without talking to your doctor first.</li>
<li>You can take DEXILANT with or without food.</li>
<li>Swallow DEXILANT capsules whole. </li>
<li>If you have trouble swallowing DEXILANT capsules whole, you can open the capsules and sprinkle the contents on a tablespoon of applesauce. Be sure to swallow the applesauce mixture right away. Do not chew the mixture. Do not store for later use. </li>
<li>If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Just take the next dose at your regular time. Do not take 2 doses at the same time. If you are not sure about dosing, call your doctor.</li>
<li>If you take too much DEXILANT, call your doctor right away or go to the nearest hospital or emergency room. </li>
</ul>
<p><span class="Bold">What are the possible side effects of DEXILANT?</span></p>
<p>The most common side effects of DEXILANT include:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>gas</li>
</ul>
<p><span class="Bold">Other side effects</span></p>
<p><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></span>. Tell your doctor if you get any of the following symptoms with DEXILANT:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li>face <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></li>
<li><span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">throat tightness</span></li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span></li>
</ul>
<p>Your doctor may stop DEXILANT if these symptoms happen.</p>
<ul><li>
<span class="Bold">Low magnesium levels in your body</span>. This problem can be serious. Low magnesium can happen in some people who take a proton pump inhibitor medicine for at least 3 months. If low magnesium levels happen, it is usually after a year of treatment. You may or may not have symptoms of low magnesium. </li></ul>
<p>Tell your doctor right away if you have any of these symptoms:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li>abnormal or fast heartbeat</li>
<li><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span></li>
<li>jerking movements or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> (<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span></li>
<li><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> of the hands and feet</li>
<li><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span> or <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span></li>
<li>spasm of the voice box</li>
</ul>
<p>Your doctor may check the level of magnesium in your body before you start taking DEXILANT, or during treatment, if you will be taking DEXILANT for a long period of time.</p>
<p><span class="Bold">Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span></span>. People who are taking multiple daily doses of proton pump inhibitor medicines for a long period of time may have an increased risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the hip, wrist or spine.</p>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DEXILANT. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store DEXILANT?</span></p>
<ul><li>Store DEXILANT at room temperature between 59°F to 86°F (15°C to 30°C).</li></ul>
<p><span class="Bold">Keep DEXILANT and all medicines out of the reach of children. </span></p>
<p><span class="Bold">General information about DEXILANT</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not use DEXILANT for a condition for which it was not prescribed. Do not give DEXILANT to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Patient Information Leaflet provides a summary of the most important information about DEXILANT. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information that is written for healthcare professionals.</p>
<p>For more information, go to www.DEXILANT.com or call 1-877-825-3327.</p>
<p><span class="Bold">What are the ingredients in DEXILANT?</span></p>
<p><span class="Bold">Active ingredient:</span> dexlansoprazole.</p>
<p> Inactive ingredients: sugar spheres, magnesium carbonate, sucrose, low-substituted hydroxypropyl cellulose, titanium dioxide, hydroxypropyl cellulose, hypromellose 2910, talc, methacrylic acid copolymers, polyethylene glycol 8000, triethyl citrate, polysorbate 80, and colloidal silicon dioxide. The capsule shell is made of hypromellose, carrageenan and potassium chloride. Based on the capsule shell color, blue contains FD&amp;C Blue No. 2 aluminum lake; gray contains black ferric oxide; and both contain titanium dioxide.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_785da9ea-4066-4c58-8368-5bd72ab8e76a"></a><a name="section-17"></a><p></p>
<p class="First">Distributed by<br><span class="Bold">Takeda Pharmaceuticals America, Inc.</span><br>Deerfield, IL 60015</p>
<p>DEXILANT is a trademark of Takeda Pharmaceuticals North America, Inc. and used under license by Takeda Pharmaceuticals America, Inc. Trademark registered with the U.S. Patent and Trademark office.</p>
<p>All other trademark names are the property of their respective owners.</p>
<p>©2009-2011 Takeda Pharmaceuticals America, Inc.</p>
<p>DEX006 R15<br>Revised: October 2011</p>
<br><p><br></p>
<p><span class="Bold">Additional barcode labeling by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma     74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_1d0085d1-fa71-4231-8651-15cfc6caea01"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 60 mg Capsule Bottle Label</span></p>
<p><span class="Bold">NDC</span> 54868-6152-0<br></p>
<p>30 Capsules</p>
<p><span class="Bold">DEXILANT<br>dexlansoprazole<br>delayed release<br>capsules</span></p>
<p><span class="Bold">Rx only<br>60 mg</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 60 mg Capsule Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d62d754e-2310-4912-b022-603ae925710d&amp;name=6152.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DEXILANT 		
					</strong><br><span class="contentTableReg">dexlansoprazole capsule, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6152(NDC:64764-175)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>dexlansoprazole</strong> (dexlansoprazole) </td>
<td class="formItem">dexlansoprazole</td>
<td class="formItem">60 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Methacrylic Acid - Methyl Methacrylate Copolymer (1:1)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Methacrylic Acid - Methyl Methacrylate Copolymer (1:2)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Methacrylic Acid - Ethyl Acrylate Copolymer (1:1) Type A</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium carbonate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydroxypropyl cellulose, low substituted</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydroxypropyl cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycol 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>triethyl citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carrageenan</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>potassium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>aluminum oxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Blue No. 2</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TAP;60</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6152-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022287</td>
<td class="formItem">08/19/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f517d5f1-7d2e-4231-822d-e28898925664</div>
<div>Set id: d62d754e-2310-4912-b022-603ae925710d</div>
<div>Version: 2</div>
<div>Effective Time: 20120208</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
